marin downgrad under-perform
downgrad under-perform stunningli slow bevyxxa launch
downgrad share under-perform outperform
lower target price follow disappoint
result bevyxxa sale quarter well
limit expect clear take much longer expect
product gain traction commerci assum slower ramp
sale
year respect
product lose patent protect also concern
limit traction portola bevyxxa date put product
greater risk upcom xarelto marin data see
narrow path marin scenario would read posit
bevyxxa remain bullish andexxa see downsid risk
upsid opportun given peak global sale estim product
alreadi
dcf-deriv target price /grey
incorpor updat bevyxxa sale estim along adjust
expens assumpt model drive dcf
blue sky scenario two product gener
combin sale suggest valuat grey sky
scenario combin peak sale suggest valuat
new ep estim
main risk view rapid
uptak bevyxxa andexxa current expect strong progress
cerdulatinib compani seen potenti acquisit target
valuat metric
number share
rate outperform under-perform
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
portola biopharmaceut compani focus
develop commerci novel therapeut
area thrombosi hematolog disord inflamm
patient current limit approv treatment
price aug rate outperform under-perform target price analyst
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
 close
blue sky valuat base dcf analysi driven
combin global sale bevyxxa andexxa exceed
peak
grey sky valuat base dcf analysi driven
combin sale bevyxxa andexxa peak
stock view
xarelto marin data catalyst previous discuss remain
concern possibl impact marin trial bevyxxa commerci
potenti portola effect commerci bevyxxa immedi follow
june fda approv compani would year allow physician
becom comfort product use particular indic
clearli case need discuss data context
marin data releas european societi cardiolog meet
opinion best case scenario would xarelto show posit
efficaci much bleed marin help valid concept extend
oral anticoagul acut medic ill popul prevent xarelto
commerci threat strong efficaci safeti marin would make xarelto
formid competitor one would requir less paradigm shift bevyxxa
lack effect would forc continu tri chang physician
behavior acut medic ill set
announc new ceo could swing sentiment name continu
await appoint new ceo take leadership portola follow
departur former ceo li june given numer challeng portola
face develop commerci lead asset hire
respect ceo strong commerci experi could help improv investor
confid stori sentiment stock howev assum
announc made late year leav us comfort view
stock under-perform other coverag least
gener andexxa prior approv supplement pa submiss approv
critic previous expect andexxa pa submit
shortli product approv compani track hit target
submiss end month imper pa get approv
earli allow broader uptak product given limit sale cash
bevyxxa gener believ investor expect full andexxa
launch delay would like repres risk
impress cerdulatinib data portola present back june
current model risk-adjust peak sale product news around
acceler path market potenti partner asset could lead upsid
collabor licens revenu
good sold
incom loss oper
interest incom net
incom loss incom tax
provis incom tax
net incom attribut non-controlling interest
net incom loss attribut portola
compani mention price
